Allegro™ STR Single-Use Bioreactor Platform: simplify your process scale-up journey up to 2000L
The Allegro STR Bioreactor family including their specifications, capabilities and applications are intorduced. The Bioreactor system’s key differentiators and advantages with usability aspects are briefly outlined. The process control options, aspects and data are illustrated. The engineering & performance of the technology in terms of oxygen transfer rate and mixing times are provided. The scale up and technology transfer aspects are given followed by several case studies with data demonstrating predictability, reproducibility and reliability. Furthermore, the scientific consultancy and support services offered by Pall are promoted.
Speaker
Shahin Heshmatifar
Bioprocess Application Specialist
Pall Biotech
Shahin Heshmatifar is a Senior Bioreactor Applications Scientist and a member of the Cell Culture Technologies team at Pall Biotech (SLS – IPS - Cell Culture Technologies, EMEA). Has been dedicated to training bioreactor customers and providing scientific consultancy and advice on the transfer of their processes into Pall bioreactor technologies and process optimization. Experienced Biochemical Engineer with a demonstrated history of working in R&D. Knowledgeable and skilled in Upstream and Downstream Process Development, molecular bioanalytics and GMP. Held commercial and sales role in a major global biotechnology company. Worked for a global vaccines manufacturing company as a Bioprocess Development Scientist and Project Lead.
Allegro™ STR Single-Use Bioreactor Platform: simplify your process scale-up journey up to 2000L
Scalable Upstream Process Development of Biotherapeutics
Register to learn more about improvements in current mammalian expression platforms, cell line development and scalability workflows.
Biotech | Pall Corporation webinar series
Why the introduction of X-ray sterilization technology is a critical change for single-use industry, and how gamma and X-ray irradiation compare
The market demand for gamma irradiation, the current primary method for the sterilization in SUT, will soon significantly exceed supply, creating an urgent need for alternatives.
Join Christelle Marcoux from GSK Vaccines (BioPhorum workstream member on alternatives to gamma sterilization) and James Hathcock, PhD of Pall Corporation (Bio-Process Systems Alliance X-Ray Committee Co-Chair) as they discuss the introduction of X-ray sterilization technology.
You will learn more about:
- Why this is a critical change for industry and the responsibilities of each stakeholder
- Key questions to address for biomanufacturers
- How gamma and X-ray irradiation compare
- What testing has been completed and key milestones for readiness for industry
- An example of how to qualify a SUS sterilized with X-ray irradiation